You are viewing: South Korea Biosimulation Market analysis
Part of: Biosimulation Market (Global)

The South Korea Biosimulation Market was valued at $54.8 Million in 2026 and projected to reach to $120.1 Million by 2031, representing a compound annual growth rate of 17.0%. South Korea's biosimulation market is positioned for sustained growth through 2031, supported by the nation's commitment to biotech innovation and digital transformation in healthcare.

South Korea Biosimulation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Biosimulation Market Trends and Insights

  • This 17.0% compound annual growth rate reflects South Korea's strong investment in pharmaceutical R&D and digital health innovation.
  • South Korea's advanced healthcare infrastructure and government support for biotech development are driving adoption of biosimulation technologies across drug discovery and development pipelines. The biosimulation sector in South Korea benefits from the country's leading position in biotechnology and its highly skilled workforce.
  • South Korea's pharmaceutical companies are increasingly leveraging biosimulation to accelerate time-to-market and reduce development costs.
  • Between 2026 and 2031, South Korea is expected to consolidate its role as a regional hub for computational drug development, supported by investments in AI-driven modeling and regulatory modernization..

Key Market Statistics

  • CAGR (2026-2031) 17.0% CAGR
  • Market Size, 2026 ~USD 54.8 Million
  • Forecast, 2031 ~USD 120.1 Million
  • Country South Korea

South Korea Biosimulation Market Overview

Rapid Market Expansion :

South Korea's biosimulation market is projected to grow from USD 54.8 million in 2026 to USD 120.1 million by 2031, representing a robust 17% CAGR driven by increased pharmaceutical R&D investments and digital health adoption.

Government Support & Policy :

South Korean government initiatives promoting biotech development and digital innovation are accelerating biosimulation adoption across pharmaceutical companies and research institutions, creating favorable market conditions.

Advanced Healthcare Infrastructure :

South Korea's world-class healthcare system and strong IT infrastructure provide an ideal foundation for implementing sophisticated biosimulation technologies in drug development and clinical research.

Pharmaceutical R&D Investment :

Significant investment in pharmaceutical research and development by South Korean companies is driving demand for biosimulation tools to optimize drug discovery, reduce development timelines, and improve clinical trial efficiency.

South Korea Biosimulation Market Dynamics

  • The country's pharmaceutical sector is increasingly adopting biosimulation technologies to enhance drug development efficiency and reduce time-to-market for new therapeutics.
  • Government backing combined with private sector investment creates a dynamic ecosystem for biosimulation adoption. The market will benefit from South Korea's skilled workforce in computational biology and bioinformatics, alongside growing collaboration between academic institutions and pharmaceutical companies.
  • As regulatory frameworks evolve to recognize biosimulation in drug approval processes, adoption rates are expected to accelerate, positioning South Korea as a regional leader in biosimulation technology implementation and innovation..

Related Ecosystem

Healthcare It

Top Technologies
    Top Companies

      Key Takeaways

      • South Korea's biosimulation market is valued at USD 54.8 million in 2026 and will grow to USD 120.1 million by 2031, representing a 17.0% CAGR.
      • South Korea's advanced biotech ecosystem and government R&D incentives are accelerating biosimulation adoption among pharmaceutical developers.
      • South Korea's pharmaceutical industry is leveraging biosimulation to reduce drug development timelines and regulatory approval costs.
      • South Korea is positioned as a key Asia-Pacific hub for computational drug development and AI-driven modeling innovation.

      Biosimulation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment DATA ANALYSIS & INTERPRETATION (Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 16.7% from 2026 to 2031
      Largest Segment SOFTWARE (Offering)
      Market Size Base Year (Billions) ~USD 4.27 (2026)
      Revenue Forecast (Billions) ~USD 9.24 (2031)
      Segments Covered Offering, Type, Phase Of Development

      South Korea Biosimulation Market Report Segmentation

      3 segment dimensions are covered across the global market.

      By Offering

      • Services
      • Software

      By Type

      • Consulting & Advisory
      • Data Analysis & Interpretation
      • Implementation, Training, And Support

      By Phase Of Development

      • Commercial & Market Access
      • Drug Discovery
      • Early Clinical Development
      • Late Clinical Development
      • Preclinical Development
      • Regulatory

      Target Audience

      • Pharmaceutical Companies : South Korean and international pharma firms need market intelligence to optimize R&D investments, accelerate drug development timelines, and leverage biosimulation technologies for competitive advantage in this expanding market.
      • Biotech & Software Vendors : Biosimulation software providers and biotech solution companies require detailed South Korea market data to identify growth opportunities, assess market potential, and develop localized product strategies.
      • Healthcare Investors : Private equity, venture capital, and institutional investors need comprehensive market analysis to evaluate investment opportunities in South Korea's high-growth biosimulation and digital health sectors.
      • Research Institutions : Academic and government research organizations in South Korea need market insights to align research initiatives with industry demands and secure funding for biosimulation technology development.
      • Healthcare Consultants : Management consulting firms and healthcare advisors require South Korea-specific market data to provide strategic recommendations to clients on biosimulation adoption and digital transformation initiatives.

      Key Companies in the South Korea Biosimulation Market

      CompanyHQOwnershipStrongest segments
      SANOFIFrancePublic CompanyPediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies,
      CERTARAUnited StatesPublic CompanyBiosimulation platforms (Simcyp, Phoenix, NLME, Pirana),Regulatory data and submission software (Pinnacle 21, GlobalSubmit, CoAuthor, Metadata Repository),Discovery and informatics solutions (Chemaxon suite, D360, design tools),
      DASSAULT SYSTÈMESFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
      SCHRöDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations (e.g., Novartis),Drug Discovery – Internal Pipeline,
      SIMULATIONS PLUSUnited StatesPublic CompanyPBPK/PKPD and biopharmaceutics software (GastroPlus, DDDPlus, MembranePlus),QSP and disease-systems platforms (DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, Thales),ADMET Predictor, MedChem Designer and discovery-oriented AI/ML tools,
      PHYSIOMICS PLCUnited KingdomPublic CompanyOncology modeling & simulation (Virtual Tumour–centric consulting),Broader quantitative pharmacology & computational biology services,Personalized medicine technology and related analytics,
      INSTEM PLCUnited KingdomPrivate CompanyResearch study management software (discovery, preclinical, early clinical),Regulatory submission and SEND-compliant dataset solutions,In silico and data insights / predictive analytics,

      SANOFI

      Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees. As a public company, it operates globally in the development, manufacturing, and distribution of medicines and vaccines.

      CERTARA

      Certara is a United States-based public company founded in 2008 with 1,546 employees. It provides software and services for drug development, including modeling, simulation, and regulatory consulting.

      DASSAULT SYSTÈMES

      Dassault Systèmes is a French software company founded in 1981 with 25,724 employees. As a public company, it develops 3D design, simulation, and digital lifecycle management solutions for various industries.

      SCHRöDINGER, INC.

      Schrödinger, Inc. is a United States-based public company founded in 1990 with 850 employees. It provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

      SIMULATIONS PLUS

      Simulations Plus is a United States-based public company founded in 1996 with 213 employees. It develops software for drug development, including pharmacokinetic and pharmacodynamic modeling and simulation.

      PHYSIOMICS PLC

      Physiomics PLC is a United Kingdom-based public company founded in 2001 with 10 employees. It specializes in computational biology and systems pharmacology for drug development.

      INSTEM PLC

      Instem PLC is a United Kingdom-based private company founded in 1969 with 510 employees. It provides software and services for data management and analysis in preclinical and clinical research.

      Reasons to Buy this Report

      • Market-Specific Growth Projections : Access detailed forecasts for South Korea's biosimulation market with precise valuation data (USD 54.8M in 2026 to USD 120.1M in 2031), enabling accurate business planning and investment decisions tailored to this high-growth market.
      • Competitive Landscape Intelligence : Understand South Korea's unique competitive dynamics, including local pharmaceutical players, government initiatives, and regional partnerships that differentiate this market from global trends.
      • Regulatory & Policy Insights : Gain comprehensive understanding of South Korean government support mechanisms, biotech policies, and regulatory frameworks driving biosimulation adoption in pharmaceutical development.
      • Investment & Partnership Opportunities : Identify strategic investment opportunities and partnership potential within South Korea's growing biosimulation ecosystem, including collaborations with pharmaceutical companies and research institutions.
      • Regional Market Entry Strategy : Develop informed market entry strategies specific to South Korea with insights on local demand drivers, infrastructure capabilities, and growth catalysts for biosimulation technologies.

      Frequently asked questions

      What is the current size of South Korea's biosimulation market?

      South Korea's biosimulation market was valued at USD 54.8 million in 2026 and is expected to grow significantly through 2031.

      What is the projected growth rate for biosimulation in South Korea?

      South Korea's biosimulation market is projected to grow at a compound annual growth rate (CAGR) of 17.0% from 2026 to 2031.

      What will South Korea's biosimulation market be worth by 2031?

      South Korea's biosimulation market is forecasted to reach USD 120.1 million by 2031, more than doubling from 2026 levels.

      Why is South Korea's biosimulation market growing faster than the global average?

      South Korea's 17.0% CAGR is driven by strong government biotech support, advanced R&D infrastructure, and increasing adoption by pharmaceutical companies seeking to accelerate drug development.

      Which sectors in South Korea are driving biosimulation adoption?

      South Korea's pharmaceutical and biotechnology sectors are the primary drivers, utilizing biosimulation for drug discovery, development optimization, and regulatory compliance.

      RESEARCH METHODOLOGY

      This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.

      Secondary Research

      This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive and commercially focused study of the biosimulation market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.

      Primary Research

      In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the biosimulation market. Primary sources from the demand side included personnel from pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and regulatory bodies.

      A breakdown of the primary respondents is provided below:

      Biosimulation Market Size, and Share

      Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million. Other designations include sales managers, marketing managers, and product managers.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The total size of the biosimulation market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.

      Biosimulation Market : Top-Down and Bottom-Up Approach

      Biosimulation Market Top Down and Bottom Up Approach

      Data Triangulation

      The size of the biosimulation market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as follows: -

      • Revenues for individual companies were gathered from public sources and databases.
      • Shares of leading players in the biosimulation market were gathered from secondary sources to the extent available. In certain cases, shares of biosimulation businesses were ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength.
      • Individual shares or revenue estimates were validated through interviews with experts.
      • The total revenue in the biosimulation market was determined by extrapolating the market share data of major companies.

      Market Definition

      Biosimulation is a technology that employs computer-aided simulations to replicate and predict the dynamics of biological processes and systems. It uses modern computational power to analyze and model biological behavior through mathematical expressions. Biosimulation, often referred to as Computer-aided Drug Design (CADD), plays a critical role in various stages of drug discovery and development. Leveraging AI and machine learning, biosimulation enhances the evaluation of drug safety, efficacy, and interactions, ultimately streamlining clinical trial design and accelerating time-to-market for new therapeutics.

      Key Stakeholders

      • Clinical/Physician centers
      • Biosimulation vendors
      • Clinical research organizations
      • Pharmaceutical/Biopharmaceutical companies
      • Research & development (R&D) companies
      • Business research and consulting service providers
      • Medical research laboratories
      • Academic medical centers/Universities/Hospitals
      • Regulatory agencies
      • Clinical researchers
      • Accountable care organizations
      • Investors and venture capitalists

      Report Objectives

      • To define, describe, and forecast the biosimulation market based on offering, phase of development, modality, application, therapeutic area, deployment mode, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biosimulation market
      • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players and analyze their market shares and core competencies
      • To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall biosimulation market
      • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

      • Company information
      • Detailed analysis and profiling of additional market players (up to 5)

      Regional Analysis

      • Further breakdown of the Rest of Asia Pacific biosimulation market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
      • Further breakdown of the Rest of Europe biosimulation market into Russia, Austria, Finland, Sweden, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries

      Get the Full Biosimulation Market Report

      Full forecast, segment splits, and company analysis for all Biosimulation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status